Table 1.
Clinical features of the study population.
| Patient # |
Age (yr) |
Treatment Regimens | Receptor status |
Tumor grade |
Excised tumor size |
Pathologic response |
Surgery | ||
|---|---|---|---|---|---|---|---|---|---|
| ER | PR | HER2 | |||||||
| 1 | 50 | dd AC × 4 → Taxol × 12 | + | + | − | 3 | 0.5 | Residual disease | mastectomy |
| 2 | 52 | dd Taxotere × 4 | + | − | + | 3 | 1.5 | Residual disease | mastectomy |
| 3 | 60 | dd AC × 2 → Taxol-Herceptin × 12 | + | + | + | 1 | 2.9 | Residual disease | mastectomy |
| 4 | 36 | cisplatin/taxol +/− RAD001 × 12 | − | − | − | 2 | 2.9 | Residual disease | mastectomy |
| 5 | 48 | dd AC × 4 → Taxol × 4 | + | + | − | 1 | 1.3 | Residual disease | mastectomy |
| 6 | 43 | dd AC × 4 → Taxol × 4 | + | + | − | 2 | 2.6 | Residual disease | mastectomy |
| 7 | 59 | dd AC × 4 → Taxol × 4 | + | + | − | 2 | 4.2 | Residual disease | mastectomy |
| 8 | 53 | cisplatin/taxol +/− RAD001 × 12 | − | − | − | 2 | 1.3 | Residual disease | mastectomy |
| 9 | 35 | Trastuzumab +Carboplatin+ Ixabepilone × 6 |
+ | + | + | 3 | 1.4 | Residual disease | mastectomy |
| 10 | 28 | cisplatin/taxol +/− RAD001 × 12 | − | − | − | 3 | 0.8 | Residual disease | mastectomy |
| 11 | 33 | AC × 4 → Taxol × 12 | + | + | − | 3 | 1.2 | Residual disease | mastectomy |
| 12 | 39 | AC × 4 → Taxol × 12 | + | + | − | 1 | 2.5 | Residual disease | mastectomy |
| 13 | 57 | AC × 4 → Taxol × 12 | − | − | − | 3 | N/AΔ | Residual disease | progressed with brain mets |
| 14 | 67 | AC × 4 → Taxol/Herceptin × 12 | − | − | + | 3 | 1.8 | Residual disease | mastectomy |
| 15 | 45 | cisplatin/taxol +/− RAD001 × 12 | − | − | − | 3 | 0.5 | Residual disease | mastectomy |
| 16 | 46 | Taxotere/Carboplatin/Herceptin × 6 | + | + | + | 3 | 0.3 | Residual disease | mastectomy |
| 17 | 47 | Taxotere × 3 →dd AC × 4 | + | + | − | 1 | 8.0 | Residual disease | mastectomy |
| 18 | 36 | ddAC × 4 → Taxol × 12 | + | + | + | 2 | 1.0 | Residual disease | mastectomy |
| 19 | 43 | cisplatin/taxol +/− RAD001 × 12 | − | − | + | 3 | 0.7 | Residual disease | mastectomy |
| 20 | 55 | ddAC × 4 → Taxol × 10 | + | + | − | 2 | 3.5 | Residual disease | mastectomy |
| 21 | 58 | cisplatin/taxol +/− RAD001 × 12 | − | + | − | 2 | 1.7 | Residual disease | mastectomy |
| 22 | 36 | ddAC × 4 → Taxol × 12 | + | + | − | 2 | 2.1 | Residual disease | mastectomy |
| 23 | 43 | cisplatin/taxol +/− RAD001 × 12 | − | − | − | 3 | 1.4 | Residual disease | mastectomy |
| 24 | 42 | cisplatin/taxol +/− RAD001 × 6 | + | + | − | 2 | 3.5 | Residual disease | mastectomy |
| 25 | 53 | dd AC × 4 → Taxol-Herceptin × 7 | − | − | + | 3 | 0 | pCR | mastectomy |
| 26 | 46 | ddTaxotere→AC | − | + | − | 3 | 0 | pCR | mastectomy |
| 27 | 46 | dd AC × 4 → Taxol-Herceptin × 12 | − | − | + | 2 | 0 | pCR | mastectomy |
| 28 | 33 | ddAC × 4 → Taxol × 12 | − | − | − | 3 | 0 | pCR | mastectomy |
| 29 | 39 | Trastuzumab and Lapatinib × 12 | − | − | + | 2 | 0 | pCR | mastectomy |
| 30 | 46 | ddAC × 4 → Taxol × 12 | + | − | − | 3 | 0 | pCR | mastectomy |
| 31 | 42 | cisplatin/taxol +/− RAD001 × 12 | − | − | − | 3 | 0 | pCR | mastectomy |
| 32 | 34 | ddTaxotere→AC | − | − | − | 3 | 0 | pCR | mastectomy |
| 33 | 44 | Trastuzumab and Lapatinib × 12 | − | − | + | 3 | 0 | pCR | mastectomy |
| 34 | 37 | cisplatin/taxol +/− RAD001 × 11 | − | − | − | 3 | 0 | pCR | mastectomy |
| 35 | 39 | ddAC × 4 → Taxol × 10 | − | − | − | 3 | 0 | pCR | mastectomy |
| 36 | 48 | Taxotere/Carboplatin/Herceptin × 5 | − | − | + | 3 | 0 | pCR | mastectomy |
| 37 | 51 | ddAC × 4 → Taxol × 12 | − | − | − | 3 | 0 | pCR | mastectomy |
§
The study is ongoing and we are blinded to the randomization.
Δ
This patient was transferred to another hospital and the tumor size is not available.